QuatRx Pharmaceuticals Co
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From QuatRx Pharmaceuticals Co
News We’re Watching – FDA Nixes Neuralink Trials, Layoffs at J&J, Novel Knee Implants
This week, we learned that the US FDA thinks Elon Musk’s Neuralink brain interface device isn’t ready for human trials. Additionally, J&J cut about 300 medtech jobs, Stryker launched a knee implant, and Active Implants’ meniscus replacement device made it to the FDA’s advisory panel calendar.
Dealmaking Quarterly Statistics, Q4 2022
During Q4, biopharma merger and acquisition value reached $35.7bn and drew in $62.1bn in potential deal value from alliances. Device company M&A values reached $19.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.8bn.
Financing Quarterly Statistics, Q4 2022
During Q4, biopharmas brought in an aggregate $17.5bn in financing and device company fundraising totaled $1.9bn; while in vitro diagnostic firms and research tools players raised $848m.
As Magrolimab AML Studies Chug Along, The Question Becomes How To Combine It
With an FDA hold lifted and enrollment moving quickly, physicians are looking at how to combine magrolimab with other treatments in patients with TP53-mutated AML.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
- Other Names / Subsidiaries
-
- Hormos Medical
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice